Get the Stockscreener App
1.43
16.26%
0.20
After Hours:
1.44
0.01
+0.70%
Invivyd Inc stock is traded at $1.43, with a volume of 10.25M.
It is up +16.26% in the last 24 hours and up +83.26% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.23
Open:
$1.24
24h Volume:
10.25M
Relative Volume:
2.04
Market Cap:
$171.80M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.7296
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
+25.44%
1M Performance:
+83.26%
6M Performance:
+69.73%
1Y Performance:
+24.35%
1-Day Range:
$1.05
$1.45
1-Week Range:
$1.05
$1.45
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.43 | 270.10M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Should you avoid Invivyd Inc. stock right nowPortfolio Update Summary & Precise Swing Trade Entry Alerts - Lancaster City Council
Invivyd at H.C. Wainwright Conference: Expanding Beyond COVID By Investing.com - Investing.com Australia
Invivyd at H.C. Wainwright Conference: Expanding Beyond COVID - Investing.com
Live Chart Scan Detects Wedge Pattern in Invivyd Inc.2025 Trading Volume Trends & Expert-Curated Trade Recommendations - beatles.ru
Is Invivyd Inc. a speculative investmentTrade Entry Report & Accurate Buy Signal Notifications - beatles.ru
Invivyd, Inc. $IVVD Shares Sold by Redmile Group LLC - MarketBeat
Invivyd Secures FDA Pathway and Reports Strong Neutralization Data - StocksToTrade
Maverick Capital Ltd. Has $6.63 Million Holdings in Invivyd, Inc. $IVVD - MarketBeat
What does recent volatility data suggest for Invivyd Inc.Earnings Miss & Smart Money Movement Tracker - Newser
Technical analysis overview for Invivyd Inc. stockJuly 2025 Opening Moves & Risk Controlled Swing Trade Alerts - Newser
How to escape a deep drawdown in Invivyd Inc.July 2025 Analyst Calls & Daily Technical Forecast Reports - Newser
Could Invivyd's (IVVD) New Study Design Hint at a Pivotal Strategy for Tackling Long COVID? - simplywall.st
Could Invivyd's (IVVD) Expanding Antibody Pipeline Redefine Its Long-Term Therapeutic Strategy? - Yahoo Finance
Does Invivyd Inc. stock have upside surprise potentialWeekly Trend Summary & Proven Capital Preservation Tips - خودرو بانک
Is Invivyd Inc. gaining market shareJuly 2025 Opening Moves & Technical Analysis for Trade Confirmation - خودرو بانک
Why is Invivyd Inc. stock going upTrade Exit Summary & Detailed Earnings Play Strategies - خودرو بانک
Analyzing recovery setups for Invivyd Inc. investorsJuly 2025 Trends & Safe Capital Growth Tips - Newser
Custom watchlist performance reports with Invivyd Inc.Global Markets & Long-Term Safe Investment Plans - Newser
Can Invivyd Inc. hit a new high this monthWeekly Gains Summary & Smart Money Movement Alerts - Newser
Has Invivyd Inc. formed a bullish divergenceMarket Movement Recap & Community Driven Trade Alerts - Newser
Price momentum metrics for Invivyd Inc. explainedJuly 2025 Opening Moves & Free Weekly Watchlist of Top Performers - Newser
Will Invivyd Inc. bounce back from current supportTrade Performance Summary & Precise Buy Zone Tips - Newser
Is Invivyd Inc. impacted by rising rates2025 Investor Takeaways & Real-Time Volume Spike Alerts - خودرو بانک
Senior Manager/Associate Director, Marketing Waltham/Bostonwill consider remo at Invivyd - Mediabistro
Analyzing Invivyd Inc. with risk reward ratio chartsJuly 2025 Action & Expert Curated Trade Setups - Newser
Can technical indicators confirm Invivyd Inc.’s reversal2025 Trading Recap & Growth Focused Entry Reports - Newser
Volume spikes in Invivyd Inc. stock – what they mean2025 Major Catalysts & Community Trade Idea Sharing - Newser
Chart based exit strategy for Invivyd Inc.Weekly Investment Summary & Stock Market Timing Techniques - Newser
Is now a turning point for Invivyd Inc.July 2025 Opening Moves & Low Risk Entry Point Guides - Newser
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Invivyd Inc - GuruFocus
Market reaction to Invivyd Inc.’s recent newsJuly 2025 EndofMonth & Safe Entry Trade Reports - Newser
Trend analysis for Invivyd Inc. this weekMarket Activity Summary & Breakout Confirmation Alerts - Newser
Invivyd, Inc. Announces SPEAR Study Group's Proposal for Clinical Study on Monoclonal Antibodies for Long COVID Treatment - Quiver Quantitative
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025 - The Manila Times
Invivyd's VYD2311 to be Tested in Recommended Long COVID Antibody Study Design - AInvest
Is Invivyd Inc. still a buy after recent gainsJuly 2025 Highlights & AI Powered Market Entry Strategies - خودرو بانک
What machine learning models say about Invivyd Inc.2025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Understanding Invivyd Inc.’s price movementMarket Performance Summary & AI Driven Price Forecasts - Newser
Invivyd at Cantor Global Healthcare: Strategic Moves in COVID-19 Antibody Space - Investing.com
Will Invivyd Inc. see short term momentumPortfolio Value Report & Free Weekly Watchlist of Top Performers - Newser
How to monitor Invivyd Inc. with trend dashboardsQuarterly Portfolio Summary & Daily Entry Point Alerts - Newser
Pattern recognition hints at Invivyd Inc. upsideWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
What analysts say about Invivyd Inc. stockJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - خودرو بانک
Long term hold vs stop loss in Invivyd Inc.Oil Prices & AI Optimized Trading Strategy Guides - Newser
Live market analysis of Invivyd Inc.2025 Trading Volume Trends & Real-Time Volume Surge Alerts - Newser
Applying Elliott Wave Theory to Invivyd Inc.July 2025 Retail & Risk Managed Investment Signals - Newser
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):